Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics reported positive multiple-ascending dose (MAD) data from its Phase 1 proof-of-concept trial of GlyphAgo in healthy volunteers. The data confirmed favorable safety, tolerability, and pharmacokinetics, with no liver-related adverse events observed across all dose levels.
Key figures
- Drug Name
- GlyphAgo (SPT-320)
- Phase Of Trial
- Phase 1
- Participants
- 174
- Bioavailability increase
- 6.8-fold
- Pk variability reduction
- 10-fold
- Dose normalized exposure increase
- 9.6 to 14.5-fold
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.